Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can your lung bacteria predict antibiotic failure?

NCT ID NCT06916481

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines how the community of bacteria in the lungs (the microbiome) affects how well pneumonia patients respond to antibiotics. Researchers will follow 300 adults with pneumonia, taking samples from the mouth, rectum, and lungs over 90 days. The goal is to see if the initial bacteria profile can predict treatment failure or the rise of antibiotic resistance, potentially leading to more personalized antibiotic choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which pneumonia patients will respond to antibiotics, reducing treatment failures and antibiotic resistance.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results may not apply to all pneumonia patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population of interest is specific to each cohort. \> For cohort 1: patients will be informed orally and in writing by the investigator on the delegation log during their hospitalization before inclusion. Patients will be informed of their right to decline participation and an informed written consent will be obtained by the investigator for biobank collection. \> For cohorts 2 and 3: some patients may not be able to decline participation (sedated, ventilated). In these cases, relatives, if they are present, will be informed orally and in writing by the investigator on the delegation log. Relatives will be informed of their right to decline participation on behalf of the patient. Patients will be informed as soon as their health allows it. Patients will be informed of their right to decline to continue, and of their right to forbid the use of already collected data and/or samples.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cohort 1: CAP at emergency department and requiring hospitalization in general wards : * Age ≥18 years * Hospitalization in a medical department (not ICU) * Presence of at least one acute clinical sign compatible with pneumonia (e.g. dyspnea, cough, purulent sputum or purulent tracheal aspirations or crackles), and temperature above 38°C in the 48 hours prior to inclusion * AND new pulmonary infiltrate on chest X-ray or CT scan (on Day 0 or within three days of inclusion) * Efficient treatment initiated for less than 24 hours * Sputum collection possible * Cohort 2: Severe CAP with ICU hospitalization : * Age ≥18 years * Hospitalization in intensive care unit for at least 24 hours. * Presence of at least one acute clinical sign compatible with pneumonia (e.g. dyspnoea, cough, purulent sputum or crackles), temperature greater than 38°C in the 48 hours prior to hospital admission * AND new pulmonary infiltrate on chest X-ray or CT scan (on Day 0 or within three days of inclusion) * Efficient treatment initiated for less than 24 hours * Sputum collection or tracheal aspiration or any distal bacterial sample (BAL, plugged telescopic catheter) collection possible * Cohort 3: vHAP or VAP : * Age ≥18 years * vHAP: mechanical ventilation, in a patient previously hospitalized for more than 48 hours at the onset of new or worsening radiological infiltrates and 2 of the following: fever or hypothermia, leukocytosis \> 12 G/L or leukopenia \< 4G/L, purulent tracheal aspirates, * VAP: mechanical ventilation for more than 48 hours, new or worsening radiological infiltrates and 2 of the following: fever (\>38°C) or hypothermia (\<36.5°C) in the 24 hours prior to inclusion, leucocytosis\> 12 G/L or leukopenia \< 4G/L, purulent tracheal aspirates * AND plugged telescopic catheter (PTC) ≥103colony-forming units (CFU)/ml or bronchoalveolar lavage (BAL) culture ≥104 CFU/ml or purulent tracheal aspirates ≥ 106 UFC/mL * AND treated with active antibiotic therapy for pneumonia for less than 24 hours Exclusion Criteria: * Cohort 1: CAP with hospitalization in general wards : * AIDS * Patient on high-dose corticosteroids \>2 mg/kg prednisone equivalent * Bone marrow transplant patients * Cancer patients undergoing chemotherapy within 3 months of inclusion * Opposition of the patient (absence of informed written consent) * Scheduled transfer to another hospital * Patient under guardianship or comparable legal status * NB: Patients included in the cohort 1 and referred to ICU within the first 24 hours will be included in the cohort 2. * Cohort 2: Severe CAP with ICU hospitalization : * AIDS * Patient on high-dose corticosteroids \>2 mg/kg prednisone equivalent * Bone marrow transplant patients * Cancer patients undergoing chemotherapy within 3 months of inclusion * Stays shorter than 24h in the ICU will be exlcuded * Absence of informed written consent of the patient if they are fit, or absence of informed written consent of the relative/caregiver (for patients unable to understand the information and in the absence of a relative/caregiver, emergency inclusion is authorized) * Decision to forego life-sustaining therapy * Patient under guardianship or comparable legal status * Cohort 3: vHAP or VAP : * AIDS * Patient on high-dose corticosteroids \>2 mg/kg prednisone equivalent * Bone marrow transplant patients * Cancer patients undergoing chemotherapy within 3 months of inclusion * Absence of informed written consent of the patient if he is fit, or absence of informed written consent of the relative (for patients unable to understand the information and in the absence of a relative, emergency inclusion is authorized) * Decision to forego life-sustaining therapy * Patient under guardianship or comparable legal status

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community acquired or acquiring hospital acquired pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Nantes

    ACTIVE_NOT_RECRUITING

    Nantes, France

  • CHU Nantes - Saint Herblain

    NOT_YET_RECRUITING

    Nantes, France

  • CHU Nantes - Saint Herblain

    NOT_YET_RECRUITING

    Nantes, France

  • Hospital Beaujon

    ACTIVE_NOT_RECRUITING

    Clichy, France

  • Hospital Bichat

    RECRUITING

    Paris, 75 018, France

  • Hospital Bichat

    ACTIVE_NOT_RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.